GFAP and early-onset autosomal dominant Alzheimer disease: P-tau181 and GFAP levels were greater in the Alzheimer’s disease group than in the other two patient groups and showed the best performance in distinguishing Alzheimer’s disease patients from SIVD (AUC = 0.922) and FTLD patients (AUC = 0.894), respectively.